Immune checkpoint inhibitors (CPIs) have opened a new era in the treatment of cancer,
and their indications are increasing rapidly. To date, these CPIs include anti-CTLA4
(ipilimumab), anti-Programmed Death 1 (PD1) (nivolumab, pembrolizumab) and anti-Programmed
Death-Ligand 1 (PD-L1) (atezolizumab, avelumab, durvalumab) antibodies (Abs). Solid
organ transplant recipients have a higher risk of neoplastic complications because
of immunosuppressive treatments and oncogenic viral infections [
[1]
]. Thus, cancer has now become the second cause of death among transplant patients
[
[2]
]. However, data are lacking regarding the use of CPI in these transplant patients
because they were excluded from clinical trials because of the theoretical risk of
organ rejection [
3
,
4
,
5
]. Only a few isolated cases of CPI use in transplant recipients have been reported
in the literature so far (reviewed in [
[6]
]). Therefore, although there is a clear medical need, the possibility of using these
new therapies in transplant patients with cancer remains largely unknown. Here, we
report a series of seven kidney allograft recipients treated with CPI for cancer.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Spectrum of cancer risk among US solid organ transplant recipients.J Am Med Assoc. 2011; 306: 1891-1901
- Malignancy after transplantation.Transplantation. 2005; 80: S254-S264
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med. 2010; 372: 2006-2017
- Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med. 2015; 373: 1627-1639
- PD 1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.N Engl J Med. 2015; 372: 311-319
- Immune checkpoint Inhibitors in organ transplant patients.J Immunother. 2017; 40: 277-281
- Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.Liver Transpl. 2013; 19: 937-944
- mmune-related adverse events with immune checkpoint blockade: a comprehensive review.Eur J Cancer. 2016; 54 (Feb): 139-148
Article info
Publication history
Published online: April 26, 2018
Accepted:
March 17,
2018
Received:
March 15,
2018
Identification
Copyright
© 2018 Elsevier Ltd. All rights reserved.
